Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre, randomised, open‐label, 2-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with docetaxel or in combination with gemcitabine in the treatment of patients with metastatic non-small cell lung cancer in progression after first line treatment.

Trial Profile

A prospective, multicentre, randomised, open‐label, 2-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with docetaxel or in combination with gemcitabine in the treatment of patients with metastatic non-small cell lung cancer in progression after first line treatment.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masitinib (Primary) ; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 According to an AB Science media release, this study did not pass the pre-planned statistical analysis to detect a superiority trend in overall survival between masitinib in combination with standard-of-care chemotherapy when compared against its relevant historical meta-analysis benchmark. Therefore, the indication will not be moved to phase III.
    • 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
    • 05 Sep 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top